![Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor](/docs/US/2021-03-16/US10945771B2/abs.jpg.600x600.jpg)
- 专利标题： Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor
-
申请号： US16620046申请日： 2018-06-04
-
公开(公告)号： US10945771B2公开(公告)日： 2021-03-16
- 发明人: Dane James Clausen , James I. Fells , Joseph A. Kozlowski , Ping Liu , Robert D. Mazzola, Jr.
- 申请人： Merck Sharp & Dohme Corp.
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 代理商 J. Eric Thies; John C. Todaro
- 国际申请： PCT/US2018/035772 WO 20180604
- 国际公布： WO2018/226545 WO 20181213
- 主分类号： A61B17/70
- IPC分类号： A61B17/70 ; A61B17/17 ; A61B17/34 ; A61B17/86 ; C07D471/04 ; C07D471/14 ; C07D498/14 ; A61B17/56 ; A61B90/00
![Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor](/abs-image/US/2021/03/16/US10945771B2/abs.jpg.150x150.jpg)
摘要：
The present invention is directed to azabicyclo[4.1.0]heptane compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.